Financial Insights Inc. Has $451,000 Holdings in Eli Lilly and Company $LLY

Financial Insights Inc. lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 578 shares of the company’s stock after selling 25 shares during the quarter. Financial Insights Inc.’s holdings in Eli Lilly and Company were worth $451,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Family CFO Inc acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $54,000. Duquesne Family Office LLC boosted its stake in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Corient IA LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $570,000. Cutter Capital Management LP acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $14,866,000. Finally, Emerald Advisors LLC boosted its stake in Eli Lilly and Company by 60.8% in the 2nd quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock valued at $796,000 after buying an additional 386 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $938.94.

Eli Lilly and Company Trading Up 2.5%

LLY stock opened at $840.46 on Friday. The company has a market cap of $795.47 billion, a P/E ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a fifty day moving average of $734.60 and a 200-day moving average of $765.98.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.